Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BSE - Delayed Quote INR

Kabra Drugs Limited (KABRADG.BO)

Compare
11.08
0.00
(0.00%)
At close: April 15 at 10:45:15 AM GMT+5:30
Loading Chart for KABRADG.BO
  • Previous Close 11.08
  • Open 11.08
  • Bid 11.08 x --
  • Ask --
  • Day's Range 11.08 - 11.08
  • 52 Week Range 10.06 - 11.08
  • Volume 102
  • Avg. Volume 1,466
  • Market Cap (intraday) 262.682M
  • Beta (5Y Monthly) -0.11
  • PE Ratio (TTM) --
  • EPS (TTM) -2.30
  • Earnings Date May 28, 2025 - Jun 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Kabra Drugs Limited does not have significant operations. Previously, it was engaged in permaculture manufacturing and trading of pharma related products. Kabra Drugs Limited was incorporated in 1989 and is headquartered in Chennai, India.

www.kabradrugs.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: KABRADG.BO

View More

Performance Overview: KABRADG.BO

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

KABRADG.BO
0.00%
S&P BSE SENSEX (^BSESN)
0.53%

1-Year Return

KABRADG.BO
10.14%
S&P BSE SENSEX (^BSESN)
7.69%

3-Year Return

KABRADG.BO
10.14%
S&P BSE SENSEX (^BSESN)
34.65%

5-Year Return

KABRADG.BO
10.14%
S&P BSE SENSEX (^BSESN)
148.67%

Compare To: KABRADG.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KABRADG.BO

View More

Valuation Measures

Annual
As of 4/16/2025
  • Market Cap

    262.68M

  • Enterprise Value

    248.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    8.01

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.49M

  • Diluted EPS (ttm)

    -2.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.88M

  • Total Debt/Equity (mrq)

    19.51%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: KABRADG.BO

View More

Company Insights: KABRADG.BO

Research Reports: KABRADG.BO

View More

People Also Watch